

This document was generated by the Reference Group to the United Nations on HIV and Injecting Drug Use.

The data included in this report reflect the results of a systematic search and review of data on a range of indicators reflecting the extent of services provided to people who inject drugs.

These data have been searched, reviewed and extracted according to decision rules developed by the Reference Group.

Some data have been adjusted to facilitate estimates of standard indicators across countries.

Details of the process for searching, grading and including data, along with their interpretation, are detailed in:

Mathers B, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick R, et al. HIV prevention, treatment and care for people who inject drugs: A systematic review of global, regional and national coverage. *The Lancet* 2010. DOI:10.1016/S0140-6736(10)60232-2.

For more information on the Reference Group, please go to:
www.IDURefGroup.Com

Section	Page
Estimated number of people who inject drugs and number of injectors who are living with HIV	4
1. Needle and syringe programs (NSPs)	5
NSP 1: Availability of NSPs	
NSP 2: Number of NSP sites	
NSP 3: Number of pharmacy sites where needles and syringes are available for purchase	
NSP 4: Total number of sites where needles and syringes are available	
NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period	
NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period	
NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period	
2. Opioid substitution programs (OST)	10
OST 1: Availability of opioid substitution treatment (OST)	
OST 2: Availability of methadone maintenance treatment (MMT)	
OST 3: Availability of buprenorphine maintenance treatment (BMT)	
OST 4: Availability of other forms of agonist OST	
OST 5: Dose and duration of MMT	
OST 6: Dose and duration of BMT	
OST 7: Total number of all sites providing OST	
OST 8: Number of sites providing MMT	
OST 9: Number of sites providing BMT	
OST 10: Number of sites providing other forms of agonist OST	
OST 11: Number of all clients in any OST at a single point in time	
OST 12: Number of all clients in MMT at a single point in time	
OST 13: Number of all clients in BMT at a single point in time	
OST 14: Number of all clients in other forms of OST at a single point in time	
OST 15: Number of IDUs in any OST at a single point in time	
OST 16: Number of IDUs in MMT at a single point in time	
OST 17: Number of IDUs in BMT at a single point in time	
OST 18: Number of IDUs in other forms of OST at a single point in time	
OST 19: Number of all clients receiving any OST in a 12 month period	
OST 20: Number of all clients receiving MMT in a 12 month period	
OST 21: Number of all clients receiving BMT in a 12 month period	
OST 22: Number of all clients receiving other forms of OST in a 12 month period	
OST 23: Number of IDUs receiving any OST in a 12 month period	
OST 24: Number of IDUs receiving MMT in a 12 month period	

Section	Page
OST 25: Number of IDUs receiving BMT in a 12 month period	
OST 26: Number of IDUs receiving other forms of OST in a 12 month period	
3. Other Drug Treatment (ODT)	23
<hr/>	
ODT 1: Detoxification	
ODT 1.1: Number of sites providing detoxification	
ODT 1.2: Number of IDUs receiving detoxification	
ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time	
ODT 2: Residential Rehabilitation	
ODT 2.1: Number of sites providing residential rehabilitation	
ODT 2.2: Number of IDUs in residential rehabilitation	
ODT 2.3: Number of all clients in residential rehabilitation	
ODT 3: Outpatient psychosocial support, counselling and psychotherapy	
ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy	
ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 4: Peer-based support groups	
ODT 4.1: Number of sites providing peer-based support groups	
ODT 4.2: Number of IDUs in peer-based support groups	
ODT 4.3: Number of all clients in peer-based support groups	
ODT 5: Drug treatment (treatment type not specified)	
ODT 5.1: Number of sites providing unspecified drug treatment	
ODT 5.2: Number of IDUs receiving unspecified drug treatment	
ODT 5.3: Number of all clients receiving unspecified drug treatment	
ODT 6: Drug treatment in prisons	
ODT 6.1: Number of drug treatment sites located in prisons	
ODT 6.2: Number of IDUs receiving drug treatment in prisons	
ODT 6.3: Number of all clients receiving drug treatment in prisons	
ODT 7: Compulsory drug treatment	
ODT 7.1: Number of compulsory detention sites for drug use	
ODT 7.2: Number of IDUs in compulsory detention sites for drug use	
ODT 7.3: Number of all drug users in compulsory detention sites for drug use	
4. HIV testing and counselling (T&C)	38
<hr/>	
T&C 1: Availability of HIV T&C	
T&C 2: Number of sites providing HIV T&C that specifically targets IDUs	

Section	Page
T&C 3: Number of T&C sites providing HIV T& to the general population and also accessible to IDUs	
T&C 4: Number of individual IDUs who were tested for HIV in a 12 month period	
T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result	
5. Anti-retro-viral (ARV) treatment	41
<hr/>	
ARV 1: Number of sites providing ARV treatment	
ARV 2: Number of IDUs receiving ARVs at a single point in time	
ARV 3: Restrictions on IDUs' access to ARVs	
6. Condoms	44
<hr/>	
Condoms 1: Availability of condom programs targeting IDUs	
Condoms 2: Number of sites distributing condoms to IDUs	
Condoms 3: Number of individual IDUs receiving condoms	
Condoms 4: Number of condoms distributed to IDUs	

Germany (Western Europe)

Estimated number of people who inject drugs and number of injectors who are living with HIV

Estimated prevalence of IDU among general population aged 15-64 years (%)	Low	Mid	High
	0.14	0.17	0.20
Year of IDU prevalence estimate	2005		
Reference for IDU prevalence estimate	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
Estimated prevalence of HIV among people who inject (%)	Low	Mid	High
	1.37	2.9	4.23
Year of HIV prevalence among IDU estimate	2006		
Reference for HIV prevalence among IDU estimate	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age in 2008	54 570 145 (source: UN Population Division, 2009)		
Estimated IDU population in 2008	Low	Mid	High
	77 000	93 000	109 000
Estimated number of IDUs living with HIV in 2008	Low	Mid	High
	1055	2697	4606

1. Needle and syringe programs (NSPs)**NSP 1: Availability of NSPs**

Are NSPs available?	Yes
Comments	
Most recent year of documentation	2008
Reference	See references for other NSP indicators
When were NSPs first introduced?	
Reference	
Are needles and syringes available for purchase from pharmacies?	
Most recent year of documentation	
Reference	

NSP 2: Number of NSP sites

Data reported	250 NSP sites		
Year of reported data	2007		
Reference	Reitox National Focal Point (2008). Germany - New developments, trends and in-depth information on selected issues. 2008 National report to the EMCDDA,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	250		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Number of NSP sites per 1000 IDUs	Low	Mid	High
	2.28	2.67	3.23

NSP 3: Number of pharmacy sites where needles and syringes are available for purchase

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of pharmacy sites per 1000 IDUs	Low	Mid	High

NSP 4: Total number of sites where needles and syringes are available

Total number (NSP sites + Pharmacy sites)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Total number of sites per 1000 IDUs	Low	Mid	High

NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period

Data reported	NSP present but number not known		
Year of reported data	2007		
Reference	Reitox National Focal Point (2008). Germany - New developments, trends and in-depth information on selected issues. 2008 National report to the EMCDDA,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Percentage of IDUs in contact with NSPs in a 12 month period	Low	Mid	High
	NK	NK	NK

NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period

Data reported	NSP present but number of occasions of service not known		
Year of reported data	2007		
Reference	Reitox National Focal Point (2008). Germany - New developments, trends and in-depth information on selected issues. 2008 National report to the EMCDDA,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Number of NSP occasions of service (client contacts) in a 12 month period per IDU	Low	Mid	High
	NK	NK	NK

NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period

Data reported	32000 - 40000 syringes provided per quarter		
Year of reported data	2006		
Reference	Reitox National Focal Point (2008). Germany - New developments, trends and in-depth information on selected issues. 2008 National report to the EMCDDA,.		
Adjustments	Calculated the number of syringes distributed in the whole year		
Final/Adjusted data (to be used as indicator numerator)	12 8000 - 160000		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 893 084 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	110 000
INDICATOR: Total number of needles/syringes distributed in a 12 month period per IDU	Low	Mid	High
	1.16	1.5	2.06

NSP: All documents reviewed

(2008). UNGASS Country Reporting Format: Germany. Reporting period: January 2006-December 2007: 10.

-

Bremen Institute for Drug Research (BISDRO) University of Bremen, Centre for Interdisciplinary Addiction Research (CIAR) University of Hamburg, et al. (2008). Final report on prevention, treatment, and harm reduction services in prison, on reintegration services on release from prison and methods to monitor/analyse drug use among prisoners.

Canadian HIV/AIDS Legal Network (2006). Prison needle exchange: Lessons from a comprehensive review of international evidence and

Drug Commissioner of the Federal Government (2003). Drug consumption rooms - background information. Berlin.

European Monitoring Centre for Drugs and Drug Addiction. (2008). "Health and social responses - Statistical bulletin." Statistical Bulletin Retrieved 6 April 2009, from <http://www.emcdda.europa.eu/stats08/hsr>.

Gjesdal, S. (2004). "[Injection centers--new international experiences and Norwegian political debate]." Tidsskrift for Den Norske Laegeforening 124(21): 2785-7.

Islam, M. M. and K. Conigrave (2007). "Assessing the role of syringe dispensing machines and mobile van outlets in reaching hard-to-reach and high-risk groups of injecting drug users (IDUs): a review." Harm Reduction Journal 4(1): 14.

Jurgens, R. (2007). Interventions to address HIV in prisons: needle and syringe programmes and decontamination strategies. Geneva, World Health Organisation (WHO).

Jurgens, R. and G. Betteridge (2005). "Prisoners who inject drugs: public health and human rights imperatives." Health & Human Rights 8(2): 46-

Kerr, T., J. Kimber, et al. (2007). "The role of safer injection facilities in the response to HIV/AIDS among injection drug users." Current HIV/AIDS Reports 4(4): 158-64.

Michels, I., H. Stöver, et al. (2007). "Substitution treatment for opioid addicts in Germany." Harm Reduction Journal 4(1): 5.

Muller, O., C. Bernard, et al. (2006). The open drug scene in Frankfurt/Main. Frankfurt/Main, Frankfurt Local Drug Trend Monitoring System

Ogborne, A., V. Carver, et al. (2005). Harm reduction and drug use: an international comparative study of contextual factors influencing the development and implementation of relevant policies and programs, Canadian Centre for Substance Abuse (CCSA).

Open Society Institute (2007). "News report shows benefit of Prison Needle Exchange." Retrieved 1st December, 2008, from http://www.soros.org/initiatives/health/focus/ihrd/news/prisonnep_20041027.

Pfeiffer-Gerschel, T., Kipke, I., David-Spickermann, M. and Bartsch, G. (2007). 2007 National Report to the EMCDDA by the REITOX National Focal Point: Germany New Developments, Trends and In-Depth Information on Selected Issues Drug Situation 2006/2007: 209.

Prevention Committee (2005). Report on public policy for HIV prevention in Mainland France, Conseil national du sida.

Reitox National Focal Point (2008). Germany - New Development, Trends and in-depth information on selected issues. 2008 National report to the EMCDDA.

Reitox National Focal Point (2008). Germany - New developments, trends and in-depth information on selected issues. 2008 National report to the EMCDDA,.

Stark, K., U. Herrmann, et al. (2006). "A syringe exchange programme in prison as prevention strategy against HIV infection and hepatitis B and C in Berlin, Germany." Epidemiology & Infection 134(4): 814-9.

The Macfarlane Burnet Institute for Medical Research & Public Health Ltd (2005). Policy and programming guide for HIV/AIDS prevention and care among injecting drug users. Melbourne, World Health Organisation: department of HIV/AIDS.

United Nations Office on Drugs and Crime Office of the I.R. of Iran and Presidency Drug Control Headquarters (2008). Report - Regional seminar on "Reducing harms of drug use in Middle East, West and Central Asia". Tehran.

WHO and UNAIDS (2008). Progress on implementing the Dublin Declaration on partnership to fight HIV/AIDS in Europe & Central Asia WHO.

World Health Organisation (WHO) (2005). Status paper on prisons, drugs, and harm reduction, World Health Organisation (WHO).

Wright, N. M. J. and C. N. E. Tompkins (2004). "Supervised injecting centres." BMJ 328(7431): 100-2.

2. Opioid substitution treatment (OST)**OST 1: Availability of opioid substitution treatment (OST)**

Are any forms of agonist OST available?	Yes
Comments	
Most recent year of documentation	2007
Reference	See references for other OST indicators
When was agonist OST first available?	1992
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .

OST 2: Availability of methadone maintenance treatment (MMT)

Is MMT available?	Yes
Comments	
Most recent year of documentation	2007
Reference	See references for other OST indicators
When was MMT first available?	1992
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .

OST 3: Availability of buprenorphine maintenance treatment (BMT)

Is BMT available?	Yes
Comments	
Most recent year of documentation	2006
Reference	See references for other OST indicators
When was BMT first available?	2000
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .

OST 4: Availability of other forms of agonist OST

Are other forms of OST available?	Heroin Assisted Treatment
Comments	
Most recent year of documentation	2007
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .
When were other forms of OST first available?	2003
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .

OST 5: Dose and duration of MMT

Average/standard maintenance dose of MMT	75.2 mg
Comments	Mean dose from a sample of drug users
Year	2006
Reference	Muller, O., C. Bernard, et al. (2006). The open drug scene in Frankfurt/Main. Frankfurt/Main, Frankfurt Local Drug Trend Monitoring System (MoSyD).
Average/standard duration of MMT (range)	
Comments	
Year	
Reference	

OST 6: Dose and duration of BMT

Average/standard maintenance dose of BMT	
Comments	
Year	
Reference	
Average/standard duration of BMT (range)	
Comments	
Year	
Reference	

OST 7: Total number of all sites providing OST

Data reported	2786 sites 6626 physicians licensed to carry out substitution treatments		
Year of reported data	2007		
Reference	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO. Reitox National Focal Point (2008). Germany - New developments, trends and in-depth information on selected issues. 2008 National report to the EMCDDA,.		
Adjustments	Figures taken as range Assumed 6626 separate sites		
Final/Adjusted data (to be used as indicator numerator)	2786 - 6626		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Number of OST sites per 1000 IDUs	Low	Mid	High
	25.44	50.33	85.50

OST 8: Number of sites providing MMT

Data reported	MMT available but number of sites not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Number of MMT sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

OST 9: Number of sites providing BMT

Data reported	BMT available but number not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Number of BMT sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

OST 10: Number of sites providing other forms of agonist OST

Data reported	Other forms of OST available but number not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Number of sites providing other forms of OST per 1000 IDUs	Low	Mid	High

OST 11: Number of all clients in any OST at a single point in time

Data reported	55 315 clients in MMT 12 797 clients in BMT 275 clients receiving diamorphine prescriptions and 413 codeine treatment clients.		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	68 800		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST at census date : 100 IDUs	Low	Mid	High
	62.83	73.58	88.77

OST 12: Number of all clients in MMT at a single point in time

Data reported	55 315 clients in MMT at census date (1 July 2007)		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	55 315		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT at census date : 100 IDUs	Low	Mid	High
	50.52	59.16	71.37

OST 13: Number of all clients in BMT at a single point in time

Data reported	127 979 clients in BMT at census date (1 July 2007)		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	12 797		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT at census date : 100 IDUs	Low	Mid	High
	11.69	13.69	16.51

OST 14: Number of all clients in other forms of OST at a single point in time

Data reported	275 clients receiving diamorphine prescriptions 413 codeine treatment clients.		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	688		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST at census date : 100 IDUs	Low	Mid	High
	0.63	0.74	0.89

OST 15: Number of IDUs in any OST at a single point in time

Data reported	OST available but number of IDU on OST not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Percentage of IDUs in OST at a single point in time	Low	Mid	High
	NK	NK	NK

OST 16: Number of IDUs in MMT at a single point in time

Data reported	MMT available but number of IDUs not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Percentage of IDUs in MMT at a single point in time	Low	Mid	High
	NK	NK	NK

OST 17: Number of IDUs in BMT at a single point in time

Data reported	BMT available but number of IDUs receiving BMT not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Percentage of IDUs in BMT at a single point in time	Low	Mid	High
	NK	NK	NK

OST 18: Number of IDUs in other forms of OST at a single point in time

Data reported	Other forms of OST available but number not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Percentage of IDUs in other forms of OST at a single point in time	Low	Mid	High
	NK	NK	NK

OST 19: Number of all clients receiving any OST in a 12 month period

Data reported	OST available but number of clients on OST not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST in a 12 month period : 100 IDUs	Low	Mid	High
	NK	NK	NK

OST 20: Number of all clients receiving MMT in a 12 month period

Data reported	MMT available but number of clients not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT in a 12 month period : 100 IDUs	Low	Mid	High
	NK	NK	NK

OST 21: Number of all clients receiving BMT in a 12 month period

Data reported	BMT available but number of clients not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT in a 12 month period : 100 IDUs	Low	Mid	High
	NK	NK	NK

OST 22: Number of all clients receiving other forms of OST in a 12 month period

Data reported	Other forms of OST available but number not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST in a 12 month period : 100 IDUs	Low	Mid	High
	NK	NK	NK

OST 23: Number of IDUs receiving any OST in a 12 month period

Data reported	OST available but number of IDU on OST not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Percentage of IDUs receiving OST in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 24: Number of IDUs receiving MMT in a 12 month period

Data reported	MMT available but number of IDUs not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Percentage of IDUs receiving MMT in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 25: Number of IDUs receiving BMT in a 12 month period

Data reported	BMT available but number of IDUs receiving BMT not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Percentage of IDUs receiving BMT in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 26: Number of IDUs receiving other forms of OST in a 12 month period

Data reported	Other forms of OST available but number not known		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/hsr .		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Percentage of IDUs receiving other forms of OST at a single point in time	Low	Mid	High
	NK	NK	NK

OST: All documents reviewed

(2008). UNGASS Country Reporting Format: Germany. Reporting period: January 2006-December 2007: 10.

BISDRO University of Bremen (2005). Living with the daily dose: Comparing national policies and practices to improve access and adherence of HIV-infected drug users to anti-retroviral treatment [German].

BISDRO University of Bremen and WIAD Scientific Institute of the German Medical Association Bonn (2008). Reduction of Drug-related Crime in Prison: The impact of opioid substitution treatment on the manageability of opioid dependent prisoners.

Bremen Institute for Drug Research (BISDRO) University of Bremen, Centre for Interdisciplinary Addiction Research (CIAR) University of Hamburg, et al. (2008). Final report on prevention, treatment, and harm reduction services in prison, on reintegration services on release from prison and methods to monitor/analyse drug use among prisoners.

Canadian HIV/AIDS Legal Network (2006). Prison needle exchange: Lessons from a comprehensive review of international evidence and

Carrieri, M. P., L. Amass, et al. (2006). "Buprenorphine use: the international experience." *Clinical Infectious Diseases* 43 Suppl 4: S197-215.

European Monitoring Centre for Drugs and Drug Addiction. (2008). "Health and social responses - Statistical bulletin." *Statistical Bulletin* Retrieved 6 April 2009, from <http://www.emcdda.europa.eu/stats08/hsr>.

European Monitoring Centre for Drugs and Drug Addiction. (2009). "Health and social responses - Statistical bulletin." *Statistical Bulletin* 2009, from <http://www.emcdda.europa.eu/stats09/hsr>.

Michels, I., H. Stöver, et al. (2007). "Substitution treatment for opioid addicts in Germany." *Harm Reduction Journal* 4(1): 5.

Muller, O., C. Bernard, et al. (2006). The open drug scene in Frankfurt/Main. Frankfurt/Main, Frankfurt Local Drug Trend Monitoring System

Ogborne, A., V. Carver, et al. (2005). Harm reduction and drug use: an international comparative study of contextual factors influencing the development and implementation of relevant policies and programs, Canadian Centre for Substance Abuse (CCSA).

Pfeiffer-Gerschel, T., Kipke, I., David-Spickermann, M. and Bartsch, G. (2007). 2007 National Report to the EMCDDA by the REITOX National Focal Point: Germany New Developments, Trends and In-Depth Information on Selected Issues Drug Situation 2006/2007: 209.

Reitox National Focal Point (2008). Germany - New Development, Trends and in-depth information on selected issues. 2008 National report to the EMCDDA.

Reitox National Focal Point (2008). Germany - New developments, trends and in-depth information on selected issues. 2008 National report to the EMCDDA.

Solberg, U., G. Burkhart, et al. (2002). "An overview of opiate substitution treatment in the European Union and Norway." *International Journal of Drug Policy* 13(6): 477-484.

3. Other drug treatment (ODT)**ODT 1 - Detoxification****ODT 1.1: Number of sites providing detoxification**

Is detoxification available?	Yes		
Number of sites - data reported	Detoxification available but number not known		
Year of reported data	2009		
Reference	World Health Organisation (2009). Global health ATLAS data.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 427 876 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 000	93 000	109 000
INDICATOR: Number of detoxification sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

ODT 1.2: Number of IDUs receiving detoxification

Data reported	Detoxification available but number not known		
Year of reported data	2009		
Reference	World Health Organisation (2009). Global health ATLAS data.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 427 876 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 000	93 000	109 000
INDICATOR: Percentage of IDUs in detoxification in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in detoxification at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time

Data reported	Detoxification available but number not known		
Year of reported data	2009		
Reference	World Health Organisation (2009). Global health ATLAS data.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 427 876 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 000	93 000	109 000
INDICATOR: Ratio of number of all clients in detoxification in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all clients in detoxification at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 2 - Residential rehabilitation

ODT 2.1: Number of sites providing residential rehabilitation

Is residential rehabilitation present?			
Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of residential rehabilitation sites per 1000 IDUs	Low	Mid	High

ODT 2.2: Number of IDUs in residential rehabilitation

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in residential rehabilitation in a 12 month period	Low	Mid	High
INDICATOR: Percentage of IDUs in residential rehabilitation at a single point in time	Low	Mid	High

ODT 2.3: Number of all clients in residential rehabilitation

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of number of all drug users in residential rehabilitation in a 12 month period : number of IDUs	Low	Mid	High
INDICATOR: Ratio of number of all drug users in residential rehabilitation at a single point in time : number of IDUs	Low	Mid	High

ODT 3 - Outpatient psychosocial support, counselling and psychotherapy

ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy treatment

Is outpatient psychosocial support, counselling or psychotherapy present?	Yes		
Number of sites - data reported	Psychotherapy, counselling or psychosocial support present but number not known		
Year of reported data	2009		
Reference	World Health Organisation (2009). Global health ATLAS data.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 427 876 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 000	93 000	109 000
INDICATOR: Number of outpatient psychosocial support, counselling or psychotherapy sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment

Data reported	Psychotherapy, counselling or psychosocial support present but number not known		
Year of reported data	2009		
Reference	World Health Organisation (2009). Global health ATLAS data.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 427 876 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 000	93 000	109 000
INDICATOR: Percentage of IDUs in outpatient psychosocial support, counselling or psychotherapy in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs receiving outpatient psychosocial support, counselling or psychotherapy at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment

Data reported	Psychotherapy, counselling or psychosocial support present but number not known		
Year of reported data	2009		
Reference	World Health Organisation (2009). Global health ATLAS data.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 427 876 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 000	93 000	109 000
INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 4 - Peer-based support groups

ODT 4.1: Number of peer-based support groups sites

Are Peer-based support groups present?	Yes		
Number of sites - data reported	243 NA meetings per week		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments	Assumed each meeting per week occurs at a separate location		
Final/Adjusted data (to be used as indicator numerator)	243		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 570 145 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 000	93 000	109 000
INDICATOR: Number of peer-based support groups sites per 1000 IDUs	Low	Mid	High
	2.23	2.61	3.16

ODT 4.2: Number of IDUs in peer-based support groups

Data reported	Narcotics Anonymous present but number not known		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 570 145 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 000	93 000	109 000
INDICATOR: Percentage of IDUs in peer-based support groups in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in peer-based support groups at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 4.3: Number of all clients in peer-based support groups

Data reported	Narcotics Anonymous present but number not known		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 570 145 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 000	93 000	109 000
INDICATOR: Ratio of number of all drug users in peer-based support groups in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in peer-based support groups at a single point in time : number of IDUs	Low	Mid	High
	NK	null	null

ODT 5 - Drug treatment (treatment type not specified)

ODT 5.1: Number of drug treatment sites (treatment type not specified)

Type of drug treatment available	In-patient, out-patient and other treatment - type not specified		
Number of sites - data reported	934 outpatient units 245 in patient units 29 other sites including low-threshold facilities and treatment units in prisons		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Treatment demand indicator - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/tdi .		
Adjustments	Assume outpatient, inpatient and other units are situated at different locations and counts of sites are therefore mutually exclusive		
Final/Adjusted data (to be used as indicator numerator)	1208		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Number of drug treatment sites per 1000 IDUs	Low	Mid	High
	11.03	12.92	15.59

ODT 5.2: Number of IDUs in drug treatment (treatment type not specified)

Data reported	39 870 clients entering treatment at 110 out of 145 outpatient treatment units reporting data 6854 clients entering treatment at 50 out of 54 inpatient treatment units reporting data 1751 clients entering treatment at 68 out of 70 other treatment units reporting data 17.7% of clients entering treatment injected primary drug		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Treatment demand indicator - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/tdi .		
Adjustments	For lower bound included data on clients entering treatment only from sites reporting data For upper bound assumed average number clients accessing services per site for sites reporting data is the same as for sites for which data were not reported Number of IDUs in treatment calculated		
Final/Adjusted data for 12 month period (to be used as indicator numerator)	8580 - 10 932		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined in a 12 month period	Low	Mid	High
	7.84	10.43	14.11
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 5.3: Number of all clients in drug treatment (treatment type not specified)

Data reported	39 870 clients entering treatment at 110 out of 145 outpatient treatment units reporting data 6854 clients entering treatment at 50 out of 54 inpatient treatment units reporting data 1751 clients entering treatment at 68 out of 70 other treatment units reporting data		
Year of reported data	2007		
Reference	European Monitoring Centre for Drugs and Drug Addiction. (2009). "Treatment demand indicator - Statistical bulletin." Statistical Bulletin 2009, from http://www.emcdda.europa.eu/stats09/tdi .		
Adjustments	For lower bound included data on clients entering treatment only from sites reporting data For upper bound assumed average number clients accessing services per site for sites reporting data is the same as for sites for which data were not reported		
Final/Adjusted data for 12 month period (to be used as indicator numerator)	48 475 - 64 895		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 727 039 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	109 500
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined in a 12 month period : number of IDUs	Low	Mid	High
	0.44	0.61	0.84
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 6 - Drug treatment in prisons

ODT 6.1: Number of prison drug treatment sites

Type of drug treatment in prisons?	
Number of sites - data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data	

ODT 6.2: Number of IDUs in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

ODT 6.3: Number of all clients in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

ODT 7 - Compulsory detention as response to drug use

ODT 7.1: Number of compulsory detention sites for drug use

Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of compulsory detention sites for drug use per 1000 IDUs	Low	Mid	High

ODT 7.2: Number of IDUs in compulsory detention sites for drug use

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in compulsory detention in closed settings in a 12 month period	Low	Mid	High
INDICATOR: Percentage of IDUs in compulsory detention in closed settings at a single point in time	Low	Mid	High

ODT 7.3: Number of all drug users in compulsory detention sites for drug use

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of all drug users in compulsory detention in closed settings in a 12 month period : number of IDUs	Low	Mid	High
INDICATOR: Ratio of all drug users in compulsory detention in closed settings at a single point in time : number of IDUs	Low	Mid	High

ODT: All documents reviewed

(2008). UNGASS Country Reporting Format: Germany. Reporting period: January 2006-December 2007: 10.

Bremen Institute for Drug Research (BISDRO) University of Bremen, Centre for Interdisciplinary Addiction Research (CIAR) University of Hamburg, et al. (2008). Final report on prevention, treatment, and harm reduction services in prison, on reintegration services on release from prison and methods to monitor/analyse drug use among prisoners.

European monitoring Centre for Drugs and Drug Addiction. (2008). "Treatment demand indicator - Statistical bulletin " Statistical Bulletin Retrieved 6 April, 2009, from http://www.emcdda.europa.eu/html.cfm/index65250EN.html?type=stats&stat_category=w100&stat_type=w87&order=stat_reference&CFID=5203606&CFTOKEN=161d43f9a7fd61fb-2D894FE8-E64D-EF3F-72C0BF31D6EAF23A&jsessionId=3830aef6e3d5cdb788212d644b714373741b.

European Monitoring Centre for Drugs and Drug Addiction. (2009). "Treatment demand indicator - Statistical bulletin." Statistical Bulletin 2009, from <http://www.emcdda.europa.eu/stats09/tdi>.

Michels, I., H. Stöver, et al. (2007). "Substitution treatment for opioid addicts in Germany." Harm Reduction Journal 4(1): 5.

Muller, O., C. Bernard, et al. (2006). The open drug scene in Frankfurt/Main. Frankfurt/Main, Frankfurt Local Drug Trend Monitoring System

Pfeiffer-Gerschel, T., Kipke, I., David-Spickermann, M. and Bartsch, G. (2007). 2007 National Report to the EMCDDA by the REITOX National Focal Point: Germany New Developments, Trends and In-Depth Information on Selected Issues Drug Situation 2006/2007: 209.

Reitox National Focal Point (2008). Germany - New Development, Trends and in-depth information on selected issues. 2008 National report to the EMCDDA.

Reitox National Focal Point (2008). Germany - New developments, trends and in-depth information on selected issues. 2008 National report to the EMCDDA,.

World Health Organisation (2009). Global health ATLAS data.

4. HIV testing and counselling (T&C)

T&C 1: Availability of HIV T&C

Is T&C available?	Yes
Most recent year of data	2006
Reference	Bremen Institute for Drug Research (BISDRO) University of Bremen, Centre for Interdisciplinary Addiction Research (CIAR) University of Hamburg, et al. (2008). Final report on prevention, treatment, and harm reduction services in prison, on reintegration services on release from prison and methods to monitor/analyse drug use among prisoners.

T&C 2: Number of sites providing HIV T&C specifically targeting IDUs

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	0	0	0
INDICATOR: Number of targeted T&C sites per 1000 IDUs	Low	Mid	High

T&C 3: Number of sites providing HIV T&C sites to the general population and also accessible to IDUs

Data reported	VCT available but number not known		
Year of reported data	2006		
Reference	Bremen Institute for Drug Research (BISDRO) University of Bremen, Centre for Interdisciplinary Addiction Research (CIAR) University of Hamburg, et al. (2008). Final report on prevention, treatment, and harm reduction services in prison, on reintegration services on release from prison and methods to monitor/analyse drug use among prisoners.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 893 084 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 500	93 500	110 000
INDICATOR: Number of all T&C sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

T&C 4: Number of Individual IDUs who were tested for HIV in 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	0	0	0
INDICATOR: Percentage of individual IDUs accessing T&Cs in a 12 month period	Low	Mid	High

T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result

Year of reported data	
Reference	
Data reported for both male and female IDUs	
Adjustments	
Final/Adjusted data	
Data reported for male IDUs	
Adjustments	
Final/Adjusted data	
Data reported for female IDUs	
Adjustments	
Final/Adjusted data	

T&C: All documents reviewed

Bremen Institute for Drug Research (BISDRO) University of Bremen, Centre for Interdisciplinary Addiction Research (CIAR) University of Hamburg, et al. (2008). Final report on prevention, treatment, and harm reduction services in prison, on reintegration services on release from prison and methods to monitor/analyse drug use among prisoners.

5. Anti-retro-viral (ARV) treatment**ARV 1: Number of sites providing ARV treatment**

Data reported	200 sites		
Year of reported data	2008		
Reference	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	200		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	54 570 145 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	77 000	93 000	109 000
HIV among IDU prevalence estimate (%)	Low	Mid	High
	1.37	2.90	4.23
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
Estimated number of HIV positive IDUs at year of reported data (to be used as indicator)	Low	Mid	High
	1055	2697	4606
INDICATOR: Number of ARV treatment sites per 1000 IDUs	Low	Mid	High
	1.83	2.15	2.60
INDICATOR: Number of ARV treatment sites per 1000 IDUs living with HIV	Low	Mid	High
	43.42	74.16	189.59

ARV 2: Number of IDUs receiving ARVs at a single point in time

Data reported	3000 IDUs on HAART (Transmission route IDU) IDUs represent 17% of people on HAART with known transmission route		
Year of reported data	2002		
Reference	Donoghoe, M. C., A. R. Bollerup, et al. (2007). "Access to highly active antiretroviral therapy (HAART) for injecting drug users in the WHO European Region 2002-2004." <i>International Journal of Drug Policy</i> 18(4): 271-80.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	3000		
IDU prevalence estimate (%)	Low	Mid	High
	0.14	0.17	0.20
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
General population 15-64 years of age at year of reported data	55 582 950 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	78 500	95 000	111 000
HIV among IDU prevalence estimate (%)	Low	Mid	High
	1.37	2.90	4.23
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
Estimated number of HIV positive IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	1075	2755	4690
INDICATOR: Ratio of IDUs on ART: 100 IDUs living with HIV	Low	Mid	High
	63.96	108.89	278.96

ARV 3: Restrictions on IDUs' access to ARVs

Do restrictions exist which limit IDUs' access to ARV treatment?	
Year of reported data	
Reference	

ARV: All documents reviewed

Bremen Institute for Drug Research (BISDRO) University of Bremen, Centre for Interdisciplinary Addiction Research (CIAR) University of Hamburg, et al. (2008). Final report on prevention, treatment, and harm reduction services in prison, on reintegration services on release from prison and methods to monitor/analyse drug use among prisoners.

Donoghoe, M. C., A. R. Bollerup, et al. (2007). "Access to highly active antiretroviral therapy (HAART) for injecting drug users in the WHO European Region 2002-2004." *International Journal of Drug Policy* 18(4): 271-80.

WHO, UNAIDS., et al. (2009). *Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009*. Geneva, WHO.

6. Condoms

Condoms 1: Availability of condom programs targeting IDUs

Are condom programs targeting IDUs available?	
Comments	
Year	
Reference	

Condoms 2: Number of sites distributing condoms to IDUs

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of condom distribution sites targeting IDU per 1000 IDUs	Low	Mid	High

Condoms 3: Number of individual IDUs receiving condoms

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs receiving condoms in a 12 month period	Low	Mid	High

Condoms 4: Number of condoms distributed to IDUs

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Total number of condoms distributed per 12 month period per IDU	Low	Mid	High

Condoms: All documents reviewed

Bremen Institute for Drug Research (BISDRO) University of Bremen, Centre for Interdisciplinary Addiction Research (CIAR) University of Hamburg, et al. (2008). Final report on prevention, treatment, and harm reduction services in prison, on reintegration services on release from prison and methods to monitor/analyse drug use among prisoners.

Canadian HIV/AIDS Legal Network (2006). Prison needle exchange: Lessons from a comprehensive review of international evidence and